AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 2253661 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide 3.2 mg
Number of subjects: 12
Study 2253661 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 7361710 — intervention group
Group type: EXPERIMENTAL
Intervention: Invasive papillary cancer
Number of subjects: 35
Study 31743238 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual PT (telerehabilitation with remote clinician oversight)
Number of subjects: 306
Study 31743238 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual PT
Number of subjects: 306
Study 31743238 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 306
Study 31509953 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose protein regimen (scNPN)
Number of subjects: 274
Study 31509953 — intervention group
Group type: COMPARATOR
Intervention: High-dose protein regimen (iNPN)
Number of subjects: 274
Study 31509953 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard-dose protein regimen (scNPN)
Number of subjects: 274
Study 31509953 — intervention group
Group type: COMPARATOR
Intervention: Standard-dose protein regimen (iNPN)
Number of subjects: 274
Study 31509953 — intervention group
Group type: COMPARATOR
Intervention: Weight gain (control groups only)
Number of subjects: 274
Study 31509953 — intervention group
Group type: EXPERIMENTAL
Intervention: Head growth (intervention groups only)
Number of subjects: 274
Study 27884388 — intervention group
Group type: COMPARATOR
Intervention: 100 ml contrast medium
Number of subjects: 190
Study 27884388 — intervention group
Group type: EXPERIMENTAL
Intervention: 75 ml contrast medium via bolus shaping
Number of subjects: 190
Study 25958708 — intervention group
Group type: EXPERIMENTAL
Intervention: High-frequency oscillatory ventilation (HFOV)
Number of subjects: 49
Study 25958708 — intervention group
Group type: COMPARATOR
Intervention: Lung protective strategy ventilation (LPSV)
Number of subjects: 49
Study 23890352 — intervention group
Group type: EXPERIMENTAL
Intervention: High protein (HP) diet (1.4 g protein∙kg(‐1)∙d(‐1))
Number of subjects: 88
Study 23890352 — intervention group
Group type: COMPARATOR
Intervention: Normal protein (NP) diet (0.8 g protein∙kg(‐1)∙d(‐1))
Number of subjects: 88
Study 22186252 — intervention group
Group type: EXPERIMENTAL
Intervention: Canine fossa puncture (CFP)
Number of subjects: 110
Study 22186252 — intervention group
Group type: COMPARATOR
Intervention: Endoscopic sinus surgery (ESS) including middle meatus antrostomy (MMA)
Number of subjects: 110
Study 18705668 — intervention group
Group type: EXPERIMENTAL
Intervention: Young-High
Number of subjects: 0
Study 18705668 — intervention group
Group type: COMPARATOR
Intervention: Elderly
Number of subjects: 0
Study 18705668 — intervention group
Group type: EXPERIMENTAL
Intervention: Young-Low
Number of subjects: 0
Study 16602255 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen therapy (HBO2) administered at 2.4 or 2.0 atmospheres absolute, preceded the chemotherapy regimen
Number of subjects: 32
Study 16602255 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy regimen (six intravenous pulses of cyclophosphamide 1000mg/m2, doxorubicin 50mg/m2, and vincristine 1.5mg/m2)
Number of subjects: 32
Study 16602255 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen therapy (HBO2)
Number of subjects: 32
Study 16602255 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy regimen
Number of subjects: 32
Study 16602255 — intervention group
Group type: EXPERIMENTAL
Intervention: Trial regime (HBO2 + chemotherapy)
Number of subjects: 32
Study 12850387 — intervention group
Group type: EXPERIMENTAL
Intervention: Valsartan or amlodipine-based treatment
Number of subjects: 13449
Study 10853722 — intervention group
Group type: EXPERIMENTAL
Intervention: Early supported discharge and continued rehabilitation at home by a specialized team
Number of subjects: 83
Study 10853722 — intervention group
Group type: COMPARATOR
Intervention: Routine rehabilitation
Number of subjects: 83
Study 10853722 — intervention group
Group type: EXPERIMENTAL
Intervention: Home rehabilitation
Number of subjects: 83
Study 10423633 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostaglandin E1 (60 microg/d intravenously)
Number of subjects: 20
Study 10423633 — intervention group
Group type: EXPERIMENTAL
Intervention: Buflomedil (150 mg/d intravenously)
Number of subjects: 20
Study 8420016 — intervention group
Group type: EXPERIMENTAL
Intervention: Predictive dosing method
Number of subjects: 41
Study 8420016 — intervention group
Group type: COMPARATOR
Intervention: Physician dosing method
Number of subjects: 41
Study 8420016 — intervention group
Group type: COMPARATOR
Intervention: Individual dosing method
Number of subjects: 41
Study 3523328 — intervention group
Group type: EXPERIMENTAL
Intervention: Naproxen (500 to 1000 mg daily for five days)
Number of subjects: 25
Study 3523328 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study 3523328 — intervention group
Group type: EXPERIMENTAL
Intervention: Naproxen
Number of subjects: 25
Study 31935151 — intervention group
Group type: EXPERIMENTAL
Intervention: Nordic Musculoskeletal Questionnaire (NMQ)
Number of subjects: 1501
Study 31935151 — intervention group
Group type: EXPERIMENTAL
Intervention: Quick Exposure Check (QEC)
Number of subjects: 1501
Study 31935151 — intervention group
Group type: EXPERIMENTAL
Intervention: Ergonomic working conditions checklist
Number of subjects: 1501
Study 29979642 — intervention group
Group type: EXPERIMENTAL
Intervention: Outsmart HPV intervention
Number of subjects: 150
Study 29979642 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 150
Study 27059951 — intervention group
Group type: EXPERIMENTAL
Intervention: PF‐06291874 (150 mg once daily)
Number of subjects: 0
Study 27059951 — intervention group
Group type: EXPERIMENTAL
Intervention: PF‐06291874 (various doses)
Number of subjects: 0
Study 27059951 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 24720273 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound assessment and clinical assessment
Number of subjects: 514
Study 24720273 — intervention group
Group type: COMPARATOR
Intervention: Standard care (clinical assessment)
Number of subjects: 514
Study 22212248 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard prophylaxis (20-40 IU kg(‐1) every other day)
Number of subjects: 66
Study 22212248 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacokinetic (PK)-tailored prophylaxis (20-80 IU kg(‐1) every third day)
Number of subjects: 66
Study 22212248 — intervention group
Group type: COMPARATOR
Intervention: On-demand treatment
Number of subjects: 66
Study 22212248 — intervention group
Group type: EXPERIMENTAL
Intervention: Any prophylaxis (standard or PK-tailored)
Number of subjects: 66
Study 20826706 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeated apneas
Number of subjects: 10
Study 20826706 — intervention group
Group type: COMPARATOR
Intervention: Rebreathing
Number of subjects: 10
Study 18154942 — intervention group
Group type: EXPERIMENTAL
Intervention: Observation-only treatment condition
Number of subjects: 36
Study 18154942 — intervention group
Group type: EXPERIMENTAL
Intervention: Guided-observation treatment condition
Number of subjects: 36
Study 18154942 — intervention group
Group type: COMPARATOR
Intervention: Instructed-observation treatment condition
Number of subjects: 36
Study 16885104 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 15252291 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone depot
Number of subjects: 315
Study 11686823 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1% PVP-iodine
Number of subjects: 223
Study 11686823 — intervention group
Group type: COMPARATOR
Intervention: Non-surgical therapy
Number of subjects: 223
Study 9560747 — intervention group
Group type: EXPERIMENTAL
Intervention: Early atropine administration
Number of subjects: 0
Study 9560747 — intervention group
Group type: COMPARATOR
Intervention: Conventional atropine administration
Number of subjects: 0
Study 7875999 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin
Number of subjects: 70
Study 7875999 — intervention group
Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 70
Study 7875999 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin and Control
Number of subjects: 70
Study 3586567 — intervention group
Group type: EXPERIMENTAL
Intervention: tranexemic acid
Number of subjects: 76
Study 3586567 — intervention group
Group type: COMPARATOR
Intervention: saline
Number of subjects: 76
Study 30055974 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy with omega-3 fatty acids and acipimox
Number of subjects: 119
Study 30055974 — intervention group
Group type: COMPARATOR
Intervention: Low-fat diet
Number of subjects: 119
Study 27034624 — intervention group
Group type: EXPERIMENTAL
Intervention: Thermogenic dietary supplement
Number of subjects: 13
Study 27034624 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study 26573936 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-led clinic (NLC)
Number of subjects: 107
Study 26573936 — intervention group
Group type: COMPARATOR
Intervention: Rheumatologist-led clinic (RLC)
Number of subjects: 107
Study 23496975 — intervention group
Group type: EXPERIMENTAL
Intervention: Special care units
Number of subjects: 358
Study 23496975 — intervention group
Group type: COMPARATOR
Intervention: Open units
Number of subjects: 358
Study 20870255 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum toxin injections (20 to 100U, max 300U, every 3 months if necessary)
Number of subjects: 38
Study 20870255 — intervention group
Group type: COMPARATOR
Intervention: Conservative treatment (thiocolchicoside 16mg/day and physical rehabilitation)
Number of subjects: 38
Study 18000469 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol consumption (>5.5 g/day)
Number of subjects: 676
Study 18000469 — intervention group
Group type: EXPERIMENTAL
Intervention: Current smoking
Number of subjects: 676
Study 17141634 — intervention group
Group type: EXPERIMENTAL
Intervention: Respiratory muscle training (RMT)
Number of subjects: 30
Study 17141634 — intervention group
Group type: EXPERIMENTAL
Intervention: Cycle ergometer testing (RMT)
Number of subjects: 30
Study 17141634 — intervention group
Group type: EXPERIMENTAL
Intervention: RMT
Number of subjects: 30
Study 12707126 — intervention group
Group type: EXPERIMENTAL
Intervention: Desflurane (Group D)
Number of subjects: 48
Study 12707126 — intervention group
Group type: COMPARATOR
Intervention: Sevoflurane (Group S)
Number of subjects: 48
Study 12707126 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam premedication
Number of subjects: 48
Study 11080460 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-based model of midwifery providing continuity of care
Number of subjects: 0
Study 8957948 — intervention group
Group type: EXPERIMENTAL
Intervention: Biofeedback training with laxatives
Number of subjects: 0
Study 8957948 — intervention group
Group type: COMPARATOR
Intervention: Control group (laxatives alone)
Number of subjects: 0
Study 8957948 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (biofeedback + laxatives and laxatives alone)
Number of subjects: 0
Study 8957948 — intervention group
Group type: EXPERIMENTAL
Intervention: Biofeedback training
Number of subjects: 0
Study 8957948 — intervention group
Group type: EXPERIMENTAL
Intervention: Children with abnormal behaviour scores who were successfully treated
Number of subjects: 0
Study 10136830 — intervention group
Group type: COMPARATOR
Intervention: Oral advice from nurse on producing a sputum sample (114 patients)
Number of subjects: 224
Study 10136830 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral advice plus written instructions (110 patients)
Number of subjects: 224
Study 3771955 — intervention group
Group type: EXPERIMENTAL
Intervention: Theo-Dur Sprinkle with high water-content meal (apple sauce)
Number of subjects: 0
Study 3771955 — intervention group
Group type: EXPERIMENTAL
Intervention: Theo-Dur Sprinkle with dry meal (corn flakes and bread)
Number of subjects: 0
Study 3771955 — intervention group
Group type: EXPERIMENTAL
Intervention: Theo-Dur Sprinkle taken 5 minutes before dry meal
Number of subjects: 0
Study 3771955 — intervention group
Group type: COMPARATOR
Intervention: Theophylline administered intravenously
Number of subjects: 0
Study 31774380 — intervention group
Group type: EXPERIMENTAL
Intervention: Vision Training (VT)
Number of subjects: 24
Study 31774380 — intervention group
Group type: COMPARATOR
Intervention: No‐Vision Training (NVT)
Number of subjects: 24
Study 29851784 — intervention group
Group type: EXPERIMENTAL
Intervention: Superficial parotidectomy and elective neck dissection
Number of subjects: 100
Study 29851784 — intervention group
Group type: COMPARATOR
Intervention: Wait-and-see policy
Number of subjects: 100
Study 29851784 — intervention group
Group type: COMPARATOR
Intervention: Elective neck dissection
Number of subjects: 100
Study 27544428 — intervention group
Group type: EXPERIMENTAL
Intervention: NO-FEAR Airlines totally self-applied
Number of subjects: 57
Study 27544428 — intervention group
Group type: EXPERIMENTAL
Intervention: NO-FEAR Airlines with therapist guidance
Number of subjects: 57
Study 27544428 — intervention group
Group type: COMPARATOR
Intervention: Waiting list control group
Number of subjects: 57
Study 27544428 — intervention group
Group type: EXPERIMENTAL
Intervention: NO-FEAR Airlines (both conditions)
Number of subjects: 57
Study 24719394 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-step irradiance
Number of subjects: 0
Study 24719394 — intervention group
Group type: COMPARATOR
Intervention: Single-dose 100 mg tramadol sustained-release tablets
Number of subjects: 0
Study 22241810 — intervention group
Group type: EXPERIMENTAL
Intervention: Telehealth intervention
Number of subjects: 102
Study 22241810 — intervention group
Group type: COMPARATOR
Intervention: Usual care plus education (Control)
Number of subjects: 102
Study 20363710 — intervention group
Group type: EXPERIMENTAL
Intervention: Yellow‐lens glasses to represent age‐related color vision changes
Number of subjects: 0
Study 20363710 — intervention group
Group type: COMPARATOR
Intervention: No intervention (control group)
Number of subjects: 0
Study 17534855 — intervention group
Group type: EXPERIMENTAL
Intervention: Prospective screening for HLA-B*5701
Number of subjects: 0
Study 16006861 — intervention group
Group type: EXPERIMENTAL
Intervention: Transperitoneal laparoscopic adrenalectomy (TLA)
Number of subjects: 57
Study 16006861 — intervention group
Group type: COMPARATOR
Intervention: Retroperitoneal laparoscopic adrenalectomy (RLA)
Number of subjects: 57
Study 12804844 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal virosomal influenza vaccine
Number of subjects: 127
Study 12804844 — intervention group
Group type: COMPARATOR
Intervention: Control placebo
Number of subjects: 127
Study 10569658 — intervention group
Group type: EXPERIMENTAL
Intervention: Propafenone (600 mg for the first 24 hours, with a possible repeated dose of 300 mg for 24 hours)
Number of subjects: 86
Study 10569658 — intervention group
Group type: COMPARATOR
Intervention: Amiodarone (30 mg/kg for the first 24 hours, with a possible repeated dose of 15 mg/kg for 24 hours)
Number of subjects: 86
Study 8712137 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily exercise and a low-fat diet according to the American Heart Association's recommendation phase III
Number of subjects: 113
Study 8712137 — intervention group
Group type: COMPARATOR
Intervention: Control group (usual care by private physician)
Number of subjects: 113
Study 1682644 — intervention group
Group type: EXPERIMENTAL
Intervention: Misoprostol (200-600 micrograms)
Number of subjects: 33
Study 1682644 — intervention group
Group type: EXPERIMENTAL
Intervention: Misoprostol (200-1000 micrograms) after 200 mg mifepristone
Number of subjects: 33
Study 1682644 — intervention group
Group type: EXPERIMENTAL
Intervention: Misoprostol after mifepristone
Number of subjects: 33
Study 1682644 — intervention group
Group type: COMPARATOR
Intervention: Misoprostol alone
Number of subjects: 33
Study 7184401 — intervention group
Group type: EXPERIMENTAL
Intervention: Buprenorphine 0.2 mg
Number of subjects: 31
Study 7184401 — intervention group
Group type: EXPERIMENTAL
Intervention: Buprenorphine 0.3 mg
Number of subjects: 31
Study 7184401 — intervention group
Group type: COMPARATOR
Intervention: Pentazocine 30 mg
Number of subjects: 31
Study 30908129 — intervention group
Group type: EXPERIMENTAL
Intervention: Binge drinking
Number of subjects: 743
Study 29727332 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy (capecitabine plus oxaliplatin)
Number of subjects: 592
Study 29727332 — intervention group
Group type: COMPARATOR
Intervention: Surgery only (control group)
Number of subjects: 592
Study 29051561 — intervention group
Group type: EXPERIMENTAL
Intervention: MAGT1-mediated disturbance of Mg2+ homeostasis
Number of subjects: 0
Study 29051561 — intervention group
Group type: COMPARATOR
Intervention: Control of HBV infection
Number of subjects: 0
Study 27417980 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated, closed-loop feedback system with mobile health technology (mHealth) data on health behaviors and clinical recommendations
Number of subjects: 68
Study 27417980 — intervention group
Group type: COMPARATOR
Intervention: Standard of care recommendations and weekly health behavior reports for self-guided care
Number of subjects: 68
Study 24306460 — intervention group
Group type: EXPERIMENTAL
Intervention: Multilinguistic intervention with a phonological and orthographic awareness emphasis
Number of subjects: 20
Study 24306460 — intervention group
Group type: EXPERIMENTAL
Intervention: Multilinguistic intervention with an additional morphological awareness focus
Number of subjects: 20
Study 24306460 — intervention group
Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 20
Study 23047380 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-port laparoscopic cholecystectomy (SPLC)
Number of subjects: 54
Study 23047380 — intervention group
Group type: COMPARATOR
Intervention: Multiport laparoscopic cholecystectomy (MPLC)
Number of subjects: 54
Study 19651267 — intervention group
Group type: EXPERIMENTAL
Intervention: 21-gauge needle
Number of subjects: 77
Study 19651267 — intervention group
Group type: EXPERIMENTAL
Intervention: 23-gauge needle
Number of subjects: 77
Study 19651267 — intervention group
Group type: EXPERIMENTAL
Intervention: 25-gauge needle
Number of subjects: 77
Study 19651267 — intervention group
Group type: COMPARATOR
Intervention: Pain intensity during injection (VAS)
Number of subjects: 77
Study 17477785 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-visit education and invitation intervention
Number of subjects: 304
Study 17477785 — intervention group
Group type: COMPARATOR
Intervention: Control group (no home visit education)
Number of subjects: 304
Study 15241909 — intervention group
Group type: EXPERIMENTAL
Intervention: Resin-modified glass ionomer cement (RMGIC) in large cavities
Number of subjects: 151
Study 11939159 — intervention group
Group type: EXPERIMENTAL
Intervention: GnRH agonists
Number of subjects: 0
Study 11939159 — intervention group
Group type: COMPARATOR
Intervention: hCG
Number of subjects: 0
Study 10719298 — intervention group
Group type: COMPARATOR
Intervention: BANS 256 microgram
Number of subjects: 217
Study 10719298 — intervention group
Group type: COMPARATOR
Intervention: BANS 64 microgram
Number of subjects: 217
Study 10719298 — intervention group
Group type: COMPARATOR
Intervention: BANS (both dosages)
Number of subjects: 217
Study 10719298 — intervention group
Group type: COMPARATOR
Intervention: BANS
Number of subjects: 217
Study 8633968 — intervention group
Group type: EXPERIMENTAL
Intervention: Video-assisted thoracic surgery (VATS)
Number of subjects: 66
Study 8633968 — intervention group
Group type: EXPERIMENTAL
Intervention: Transaxillary minithoracotomy (TAMT)
Number of subjects: 66
Study 1289512 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol (At) 50 mg/day
Number of subjects: 20
Study 1289512 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrendipine (Ni) 40 mg/day
Number of subjects: 20
Study 1289512 — intervention group
Group type: COMPARATOR
Intervention: Placebo therapy
Number of subjects: 20
Study 6428425 — intervention group
Group type: EXPERIMENTAL
Intervention: tocainide
Number of subjects: 15
Study 6428425 — intervention group
Group type: EXPERIMENTAL
Intervention: propafenone
Number of subjects: 15
Study 31172607 — intervention group
Group type: EXPERIMENTAL
Intervention: Xenogeneic block loaded with rhBMP‐2
Number of subjects: 24
Study 31172607 — intervention group
Group type: COMPARATOR
Intervention: Autogenous bone block
Number of subjects: 24
Study 30091443 — intervention group
Group type: EXPERIMENTAL
Intervention: ERAS
Number of subjects: 62
Study 30091443 — intervention group
Group type: COMPARATOR
Intervention: C
Number of subjects: 62
Study 27103031 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral 20 mL 0.3% ropivacaine and 2 mL dexmedetomidine (0.5 µg/kg) (group RD)
Number of subjects: 60
Study 27103031 — intervention group
Group type: COMPARATOR
Intervention: Bilateral 20 mL 0.3% ropivacaine and 2 mL 0.9% normal saline (group R)
Number of subjects: 60
Study 27103031 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (group R and group RD)
Number of subjects: 60
Study 24901918 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressive eccentric and concentric training for 12 weeks on the Monitorized Functional Squat System (MFSS)
Number of subjects: 33
Study 24901918 — intervention group
Group type: COMPARATOR
Intervention: Standard rehabilitation protocol (control group)
Number of subjects: 33
Study 22279214 — intervention group
Group type: EXPERIMENTAL
Intervention: Mirror visual feedback (MVF) intervention
Number of subjects: 0
Study 22279214 — intervention group
Group type: EXPERIMENTAL
Intervention: Mirror visual feedback (MVF) following continuous theta burst stimulation (cTBS)
Number of subjects: 0
Study 22279214 — intervention group
Group type: COMPARATOR
Intervention: Repetitive motor training of the nontarget hand without MVF
Number of subjects: 0
Study 22279214 — intervention group
Group type: COMPARATOR
Intervention: Continuous theta burst stimulation (cTBS) over the M1
Number of subjects: 0
Study 20166008 — intervention group
Group type: EXPERIMENTAL
Intervention: Increasing the number of steps walked each day for 24 weeks
Number of subjects: 174
Study 20166008 — intervention group
Group type: COMPARATOR
Intervention: Brisk walking at target heart rate for 20 min or more on two or more days a week
Number of subjects: 174
Study 19548513 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-based decision support
Number of subjects: 0
Study 19548513 — intervention group
Group type: EXPERIMENTAL
Intervention: Alternative financing strategies for decision support systems
Number of subjects: 0
Study 15982464 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 day training course in aggression management
Number of subjects: 0